The FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under ...

Yesterday the Vaccine Integrity Project (VIP), a panel of leading public health and policy experts, published a viewpoint on ...

The hearing was supposed to focus on the Trump administration’s 2026 budget request, but instead covered a wide range of ...

The FDA is tightening its regulatory policy around COVID vaccines with a new framework that raises the bar for certain ...

Food and Drug Administration Commissioner Marty Makary promised stakeholders last week that the agency’s new Covid-19 vaccine ...

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels about heart inflammation.

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...

The U.S. government has not yet made its official recommendations for who should be able to get COVID booster shots this fall ...

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...

The rollout of updated Covid vaccines for healthy children and adults this fall is likely to be delayed after the FDA said it ...

The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 ...

The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that ...